Project Grant R01NS134895
- Federal Project Grant Award Summary Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) received a $616,031 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 5, 2026, with completion targeted for February 28, 2031. The grant funds research investigating the role of arterial endothelial pannexin 1 (PANX1) channels...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 1, 2025, with a completion date of July 31, 2027. The award supports research investigating post-ischemic protection of white matter (WM) following ischemic stroke, addressing...
- Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Icahn School of Medicine at Mount Sinai a $629,796 Project Grant on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support research on computational mapping of cerebral metabolism during development through July 31, 2030. The project addresses critical gaps in understanding metabolic pathways that regulate brain growth by tracking,...
- Grant Award Summary Oregon Health & Science University received a $247,702 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded December 1, 2025, with completion targeted for May 31, 2028. The research project investigates neuronal and glial mechanisms regulating PAIR1 local pruning—the process by which developing nervous systems eliminate...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate how aging produces ultrastructural alterations to neuronal autophagy, which is critical for maintaining neuronal homeostasis and function. The $429,000 award to the University of Texas Health Science Center at Houston will be used to accomplish two specific aims over the 2-year project period starting January 1, 2025: Compare the ultrastructural features of axonal autophagic...
- This $399,345 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate novel therapeutic strategies for improving outcomes of acute ischemic stroke (AIS) in older mice. The key research objectives are to: (1) Rejuvenate age-associated reductions in endothelial cell (EC) autophagy and restore EC glucose transporter 1 (GLUT1) expression to improve EC function and AIS outcomes; and (2) Evaluate whether the approved drug bryostatin-1 can...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $129,186.00 to the University of California, San Diego on July 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This award supports an 18-month research initiative examining metabolic plasticity and neuronal resilience in response to chronic mitochondrial DNA (mtDNA) damage. The project...
- Grant Award Summary The University of Massachusetts Medical School received a $452,783 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) beginning June 1, 2026 and concluding May 31, 2028. This award supports biomedical research directed toward understanding molecular mechanisms of neuronal cell death and neurodegeneration, with particular emphasis on protecting the brain from Alzheimer's disease. The research investigates the relationship...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,830,581 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Johns Hopkins University. The grant supports in-depth characterization of the mechanism of action of a new macrocycle molecule called RAPIREON, which selectively activates the nuclease activity of the IRE1 protein in the unfolded protein response (UPR) pathway....
- This federal Project Grant award, totaling $2,683,965.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the establishment of a human microphysiological system to elucidate cellular mechanisms underlying vulnerability to Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...
DYSFUNCTIONAL ORGANELLE-SPECIFIC AUTOPHAGY LEADS TO BRAIN ISCHEMIA-REPERFUSION INJURY - PROJECT SUMMARY: TRANSIENT CEREBRAL ISCHEMIA OCCURS IN VARIOUS CLINICAL SCENARIOS, INCLUDING TRANSIENT ISCHEMIC ATTACK (TIA), CARDIAC ARREST, HYPOVOLEMIC SHOCK, CARDIAC SURGERY, AND MEDICAL CONDITIONS RELATED TO BRAIN EDEMA OR BRAIN VASOSPASM. THE MAJORITY OF CEREBRAL ISCHEMIA SURVIVORS EXPERIENCE LONG-TERM NEUROLOGICAL SEQUELAE DUE TO BRAIN ISCHEMIA-REPERFUSION INJURY (IRI). THE OBJECTIVE OF THE PROPOSED RESEARCH IS TO INVESTIGATE A NOVEL MECHANISM OF THE DYSFUNCTIONAL MITOPHAGY AND THE SUBSEQUENT EXCESSIVE ACCUMULATION OF DAMAGED MITOCHONDRIA (MITO HEREAFTER) AFTER CEREBRAL ISCHEMIA. THESE DAMAGED MITO RELEASE APOPTOTIC FACTORS AND REACTIVE OXYGEN SCIENCES (ROS) CONTRIBUTING TO BRAIN IRI. MITOPHAGY, A SUBTYPE OF (MACRO)AUTOPHAGY, SELECTIVELY DELIVERS DAMAGED MITO TO LYSOSOMES FOR DEGRADATION. N-ETHYLMALEIMIDE SENSITIVE FACTOR (NSF) IS THE SOLE ATPASE FOR REGULATING CELLULAR MEMBRANE FUSION EVENTS. WE HAVE FOUND THAT NSF IS DEPOSITED INTO INACTIVE PROTEIN AGGREGATES IN NEURONS DESTINED TO DIE AFTER CEREBRAL ISCHEMIA. THESE NSF-DEFICIENT NEURONS PROGRESSIVELY ACCUMULATE WITH SUBSTANTIAL AMOUNTS OF DAMAGED MITO AND AUTOPHAGIC/MITOPHAGIC STRUCTURES, SUGGESTING THAT NSF IS A CRUCIAL LIMITING FACTOR FOR REGULATING MITOPHAGIC DEGRADATION ACTIVITY, I.E., MITOPHAGIC FLUX. FURTHERMORE, WE RECENTLY GENERATED A NOVEL NEURON-SPECIFIC NSF-DEFICIENT MOUSE LINE. IN THE ABSENCE OF BRAIN ISCHEMIA, NEURONS OF THE NSF-DEFICIENT MICE EXHIBIT A SUBSTANTIAL ACCUMULATION OF MITOPHAGIC STRUCTURES AND DAMAGED MITO, WHICH SUBSEQUENTLY LEADS TO AUTONOMOUS NEURONAL DEATH. THIS PHENOTYPE REPLICATES MAJOR NEUROPATHOLOGIC FEATURES OBSERVED IN WILDTYPE (WT) MICE AFTER CEREBRAL ISCHEMIA. MOREOVER, OUR RECENT STUDIES HAVE DEMONSTRATED THAT NSF-OVEREXPRESSION (OVEREXP) PROTECTED, WHILE NSF-DEFICIENCY EXACERBATED BRAIN IRI IN THE MOUSE MODEL. BASED ON THESE DISCOVERIES, WE PROPOSE TO TEST A NOVEL HYPOTHESIS STRONGLY SUPPORTED BY OUR DATA: NSF INACTIVATION RESULTS IN DYSFUNCTIONAL MITOPHAGY, LEADING TO AN EXCESSIVE BUILDUP OF DAMAGED MITO AFTER CEREBRAL ISCHEMIA. THESE DAMAGED MITO RELEASE APOPTOTIC FACTORS AND ROS, CONTRIBUTING TO BRAIN IRI. WE WILL TEST THIS HYPOTHESIS BY INVESTIGATING: (I) WHETHER, WHERE, AND WHY NSF INACTIVATION DISRUPTS THE MITOPHAGY PATHWAY AFTER CEREBRAL ISCHEMIA USING NSF- DEFICIENT, NSF-OVEREXP, AND WT MICE (AIM 1); AND (II) THE MECHANISM RESPONSIBLE FOR THE POST-ISCHEMIC NSF INACTIVATION AS WELL AS THE CORRESPONDING TREATMENT STRATEGIES USING PHARMACOLOGICAL AGENTS IN THE MOUSE CEREBRAL ISCHEMIA MODEL. THE PROPOSED STUDIES WILL HELP TO: (I) DETERMINE IF NSF INACTIVATION INDUCES BRAIN IRI VIA DISRUPTING MITOPHAGIC DEGRADATION ACTIVITY; (II) DISTINGUISH THE MITOPHAGY-RELATED AND -UNRELATED IMPAIRMENTS THAT ARE EXPLICITLY CAUSED BY NSF INACTIVATION FROM THOSE AFFECTED BY NSF-INDEPENDENT EVENTS; AND (III) DISCOVER THE MECHANISM AND TREATMENT STRATEGIES FOR ALLEVIATING NSF INACTIVATION AFTER CEREBRAL ISCHEMIA. THESE STUDIES WILL PROVIDE THE NECESSARY FOUNDATION FOR DEVELOPING THERAPEUTICS TO RESTORE THE MITOPHAGIC DEGRADATION ACTIVITY AFTER CEREBRAL ISCHEMIA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $607.3k | 6/20/25 | ||
| Not listed | $608.8k | 7/18/24 |